Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor.

Abstract

Four of 10 patients who were enrolled on protocols of high-dose immunosuppression with peripheral blood stem cell rescue for MS experienced neurologic worsening while receiving recombinant human granulocyte colony-stimulating factor. There was improvement when methylprednisolone was given to three of the patients, but one patient died of respiratory failure. The mechanism of the neurologic worsening is uncertain.

• Authors: H Openshaw, O Stuve, J P Antel, R Nash, B T Lund, L P Weiner, A Kashyap, P McSweeney, S Forman
• Journal: Neurology (Neurology) Vol. 54 Issue 11 Pg. 2147-50 (Jun 13 2000) ISSN: 0028-3878 [Print] United States
• PMID: 10851379 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anti-Inflammatory Agents
• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor
• Methylprednisolone

Topics

• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Female
• Granulocyte Colony-Stimulating Factor (adverse effects)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Humans
• Male
• Methylprednisolone (therapeutic use)
• Middle Aged
• Multiple Sclerosis (drug therapy)
• Paralysis (chemically induced, drug therapy)
• Recombinant Proteins